Efficacy of budipine and placebo in untreated patients with Parkinson's disease

Journal of Neural Transmission

Volumn 112, Issue 8, 2005, Pages 1015-1023

  Muller T ^a   Kuhn, W ^a   Przuntek, H ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Budipine; Parkinson's disease; Placebo

Indexed keywords

BUDIPINE; DOPAMINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROTRANSMISSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTIPARKINSON AGENTS; BASAL GANGLIA; DISABILITY EVALUATION; DOPAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PIPERIDINES; PLACEBO EFFECT; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 22244467128     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0247-3     Document Type: Article

References (36)

1. Bootsma RJ, Boulard M, Fernandez L, Mottet D (2002) Informational constraints in human precision aiming. Neurosci Lett 333: 141-145
2. Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110: 517-536
3. Carey LM, Abbott DF, Egan GF, Tochon-Danguy HJ, Donnan GA (2000) The functional neuroanatomy and long-term reproducibility of brain activation associated with a simple finger tapping task in older healthy volunteers: a serial PET study. Neuroimage 11: 124-144
4. Carson RG, Chua R, Goodman D, Byblow WD, Elliott D (1995) The preparation of aiming movements. Brain Cogn 28: 133-154
5. Claus JJ, Mohr E (1996) Attentional deficits in Alzheimer's, Parkinson's, and Huntington's diseases. Acta Neurol Scand 93: 346-351
6. Eltze M (1999) Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm (Suppl) 56: 83-105
7. Fahn S, Elton R, Members of the UPDRS Development Committee (1987) Unified Parkinson's Disease Rating Scale. Macmillan, New York, pp 153-163
8. Fuente-Fernandez R, Schulzer M, Stoessl AJ (2004) Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol Psychiatry 56: 67-71
9. Geminiani G, Cesana BM, Tamma F, Contri P, Pacchetti C, Carella F, Piolti R, Martignoni E, Giovannini P, Girotti F (1991) Interobserver reliability between neurologists in training of Parkinson's disease rating scales. A multicenter study. Mov Disord 6: 330-335
10. Henderson L, Kennard C, Crawford TJ, Day S, Everitt BS, Goodrich S, Jones F, Park DM (1991) Scales for rating motor impairment in Parkinson's disease: studies of reliability and convergent validity. J Neurol Neurosurg Psychiatry 54: 18-24
11. Hermsdorfer J, Blankenfeld H, Goldenberg G (2003) The dependence of ipsilesional aiming deficits on task demands, lesioned hemisphere, and apraxia. Neuropsychologia 41: 1628-1643
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184
13. Jackisch R, Huang HY, Reimann W, Limberger N (1993) Effects of the antiparkinsonian drug budipine on neurotransmitter release in central nervous system tissue in vitro. J Pharmacol Exp Ther 264: 889-898
14. Jellinger K, Bliesath H (1987) Adjuvant treatment of Parkinson's disease with budipine: a double-blind trial versus placebo. J Neurol 234: 280-282
15. Klinge P, Ruckert N, Schuhmann M, Dorner L, Brinker T, Samii M (2002) Neuropsychological testing to improve surgical management of patients with chronic hydrocephalus after shunt treatment. Acta Neurochir (Suppl 81): 51-53
16. Klockgether T, Wullner U, Steinbach JP, Petersen V, Turski L, Loschmann PA (1996) Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur J Pharmacol 301: 67-73
17. Lalonde R, Botez-Marquard T (1997) The neurobiological basis of movement initiation. Rev Neurosci 8: 35-54
18. Müller T (2002) Dopaminergic substitution in Parkinson's disease. Expert Opin Pharmacother 3: 1393-1403
19. Müller T, Eising EG, Reiners C, Przuntek H, Jacob M, Kuhn W (1997) 2-[123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration? Nucl Med Commun 18: 1115-1121
20. Müller T, Schafer S, Kuhn W, Przuntek H (2000) Correlation between tapping and inserting of pegs in Parkinson's disease. Can J Neurol Sci 27: 311-315
21. Müller T, Benz S, Przuntek H (2002) Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. Can J Neurol Sci 29: 73-77
22. Müller T, Kuhn W, Schulte T, Przuntek H (2003) Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Neurosci Lett 339: 25-28
23. Nutt JG, Lea ES, Van Houten L, Schuff RA, Sexton GJ (2000) Determinants of tapping speed in normal control subjects and subjects with Parkinson's disease: differing effects of brief and continued practice. Mov Disord 15: 843-849
24. Pal PK, Lee CS, Samii A, Schulzer M, Stoessl AJ, Mak EK, Wudel J, Dobko T, Tsui JK (2001) Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET. Parkinsonism Rel Disord 7: 305-309
25. Platz T, Brown RG, Marsden CD (1998) Training improves the speed of aimed movements in Parkinson's disease. Brain 121 (Pt 3): 505-514
26. Przuntek H, Müller T (1999) Clinical efficacy of budipine in Parkinson's disease. J Neural Transm (Suppl 56): 75-82
27. Przuntek H, Bittkau S, Bliesath H, Buttner U, Fuchs G, Glass J, Haller H, Klockgether T, Kraus P, Lachenmayer L, Müller D, Müller T, Rathay B, Sgonina J, Steinijans V, Teshmar E, Ulm G, Volc D (2002) Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol 59: 803-806
28. Przuntek H, Müller T, Riederer P (2004) Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 111: 201-216
29. Reynolds NC Jr, Montgomery GK (1987) Factor analysis of Parkinson's impairment. An evaluation of the final common pathway. Arch Neurol 44: 1013-1016
30. Rezai K, Andreasen NC, Alliger R, Cohen G, Swayze V, O'Leary DS (1993) The neuropsychology of the prefrontal cortex. Arch Neurol 50: 636-642
31. Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathofer S, Thomas D, Weretka S, Peth S, Kreye VA, Schoels W, Katus HA, Kiehn J, Karle CA (2003) Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol 368: 404-414
32. Spieker S, Loschmann P, Jentgens C, Boose A, Klockgether T, Dichgans J (1995) Tremorlytic activity of budipine: a quantitative study with long-term tremor recordings. Clin Neuropharmacol 18: 266-272
33. Stebbins GT, Goetz CG, Lang AE, Cubo E (1999) Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. Mov Disord 14: 585-589
34. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ (1997) Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 41: 58-64
35. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ (2003) Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 54: 93-101
36. Yoo E, Park E, Chung B (2001) Mental practice effect on line-tracing accuracy in persons with hemiparetic stroke: a preliminary study. Arch Phys Med Rehabil 82: 1213-1218